news
Inhibiting METTL3 enzyme combats acute myeloid leukaemia in mice
Scientists have developed a drug called STM2457 which inhibits a key enzyme involved in acute myeloid leukaemia.
List view / Grid view
Hit-to-Lead
news
Experimental drug shown to reverse effects of Alzheimer’s in mice
Oral doses of a new drug named CA administered to mouse models led to improvements in Alzheimer's disease, including memory.
whitepaper
Catalogue: Drug target reagents
5,000+ drug target reagents for antibody, small molecule drug discovery and development, including immune checkpoints, cytokines and kinases.
article
Targeting TNF to treat Dupuytren’s disease, frozen shoulder and POCD
Dr James Woody discusses off-patent indications for anti-TNF to address unmet patient needs in pain, inflammation and beyond.
news
MK-4482 antiviral effective against SARS-CoV-2 in hamster study
The drug MK-4482 decreased viral levels in the lungs of hamsters treated for SARS-CoV-2 infection, researchers have shown.
news
Machine learning method to design better antibody drugs developed
Researchers have developed an artificial intelligence to identify the best potential antibody drug from groups of up to a few thousand.
news
Team identifies potential drug to repurpose against melanoma
Researchers say that inhibiting NLRP3 with Dapansutrile could be an effective strategy to prevent melanoma tumour growth.
article
COVID-19, broad-spectrum therapeutics and the magic blanket paradigm
Dr Praveen Prathapan explains why broad-spectrum therapeutics need to be identified to provide a safety net against pandemics, including COVID-19.
news
Novel PF74-like small molecules developed to target HIV capsid protein
Scientists have developed PF74-like small molecules able to target the HIV-1 capsid protein, identifying four potent compounds.
webinar
Hit discovery for GPCRs: HTS or virtual screens?
8 April 2021 | By Beacon Discovery
Watch our on-demand webinar and learn from an industry expert regarding GPCR virtual screening approaches and challenges and much more.
news
X-ray screening reveals two promising SARS-CoV-2 drug candidates
Using a high-brilliance X-ray lightsource and protein crystallography, researchers have identified two drugs that inhibit the main protease of SARS-CoV-2.
article
Expanding accessible chemical space through automated high-throughput experimentation
Dr Sam Liver, Manager of the High-Throughput Molecular Discovery Laboratory at the Rosalind Franklin Institute, explains how lab automation in the form of machine learning and high‑throughput experimentation (HTE) can be implemented to enhance productivity in autonomous molecular discovery.
article
How RNA therapeutics can be used to treat retinitis pigmentosa
Sahm Nasseri discusses promising pre-clinical results of an RNA-based therapeutic developed to treat retinitis pigmentosa type 11.
news
Novel opioid could provide pain relief alternative to fentanyl
NFEPP, a new opioid, inhibited colon pain in mice with colitis but did not cause the side effects associated with use of fentanyl.
article
Developing a broadly neutralising antibody therapeutic to combat SARS-CoV-2
With the ongoing COVID-19 pandemic, new treatments continue to be urgently needed. One potential solution is antibody therapeutics, which can be used to neutralise the coronavirus and provide future immunity to patients. Here, Dr Laura Walker from Adagio Therapeutics discusses how antibodies can be used in the fight against Severe…
